Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElixirr International Regulatory News (ELIX)

Share Price Information for Elixirr International (ELIX)

Share Price is delayed by 15 minutes
Get Live Data
678.00    -16.00 (-2.31%)
Bid:
690.00
Ask:
710.00
Spread: 20.00 (2.899%)
Market Cap: £336.03m
ELIX Live PriceLast checked at - London Stock Exchange

Intraday Elixirr International Share Chart

Board Appointment

13 Jan 2025 08:06

RNS Number : 0712T
Elixirr International PLC
13 January 2025
 

 

ELIXIRR INTERNATIONAL PLC

("Elixirr", the "Company" or "Group")

Board Appointment

Further to its announcement on 10 December 2024 regarding changes to the Board, Elixirr International plc (AIM:ELIX), an established, global, award-winning, challenger consultancy, announces that Nick Willott, Chief Financial Officer and Company Secretary, has been appointed to the Board with immediate effect following completion of requisite due diligence procedures.

Nick joined Elixirr in 2020, the year of the Company's AIM IPO, and has served as the Group's Finance Director and Company Secretary since that time. Prior to joining Elixirr, Nick was the Finance Director and executive board director of the financial services division of a FTSE 250 company. Nick is a Chartered Accountant, having qualified at Deloitte and worked as a Director in M&A Advisory.

Further information is set out below with Schedule Two, paragraph (g) of the AIM Rules for Companies.

Enquiries: 

For enquiries, please refer to our Investor Contacts page:

https://www.elixirr.com/investors/investor-contacts

Elixirr International plc +44 (0)20 7220 5410  

Stephen Newton, Chief Executive Officer

Graham Busby, Deputy Chief Executive Officer

Nick Willott, Chief Financial Officer and Company Secretary

investor-relations@elixirr.com

Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker) +44 (0)20 7220 0500

Stephen Keys, Callum Davidson (Corporate Finance),

Sunila De Silva (ECM)

Peel Hunt LLP (Joint Broker) +44 (0)20 7418 8900

Neil Patel, Ben Cryer, Alice Lane, Kate Bannatyne

 

About Elixirr International plc

Elixirr is an award-winning global consulting firm working with clients across a diverse range of industries, markets and geographies.

Founded in 2009, the firm set out to be the 'challenger consultancy' and do things differently than the large corporate consultancies dominating the industry: working openly and collaboratively with clients from start to finish, delivering outcomes based on innovative thinking, not methodology, and treating each client's business like their own. Elixirr has been quoted on the AIM market of the London Stock Exchange since 2020. In addition to strong organic growth, Elixirr has acquired seven boutique firms - Den Creative, Coast Digital, The Retearn Group, iOLAP, Responsum, Insigniam and Hypothesis - to grow the Group's capabilities, diversify the business, expand into new geographies and access new clients.

Schedule Two, paragraph (g) disclosures.

Nicholas Christian Willott, aged 56, is currently or has previously been a director or partner of the following companies and partnerships within the past five years:

Current directorships or partnerships

Previous directorships or partnerships within the past five years

Elixirr Digital Limited

Vanck Limited

The Retearn Group Ltd

University Of Hertfordshire Higher Education Corporation

Elixirr Consulting (Jersey) Limited

Elixirr Digital Inc.

Hypothesis Group, LLC

 

Nick, together with his persons closely associated, currently holds 258,041 ordinary shares of 0.005 pence each in Elixirr, representing approximately 0.54% of the Company's issued share capital.

Nick was previously a director of Thomas Cook Money Limited, a subsidiary of Thomas Cook Group plc. He resigned as a director in April 2019 and left employment in June 2019. After he had left employment, Thomas Cook Group plc went into liquidation and, as a result, all its UK subsidiary companies also went into liquidation in September 2019.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAVXLBFEFLBBBQ
Date   Source Headline
25th Oct 202412:01 pmRNSDirector/PDMR Shareholding
25th Oct 20247:00 amRNSResult of Secondary Placing
24th Oct 20244:35 pmRNSProposed Secondary Placing
21st Oct 20247:00 amRNSAcquisition of Hypothesis Group, LLC
14th Oct 20247:00 amRNSRevolving Credit Facility
1st Oct 20247:00 amRNSInvestor Presentation
23rd Sep 20247:00 amRNSInterim Results
31st Jul 20245:00 pmRNSDirector/PDMR Shareholding
25th Jul 20247:00 amRNSPDMR/PCA Dealings
12th Jul 20244:15 pmRNSDirector/PDMR Shareholding
9th Jul 202411:45 amRNSPurchase of Shares by Employee Benefit Trust
3rd Jul 202410:30 amRNSDirector Dealing
25th Jun 20249:55 amRNSResult of AGM
31st May 20247:00 amRNSPosting of Annual Report and Accounts
21st May 20246:20 pmRNSDirector Declaration
24th Apr 20247:00 amRNSGrant of Share Options
22nd Apr 20247:00 amRNSFinal Results
8th Apr 20247:00 amRNSNotice of FY 23 Results and Investor Presentation
26th Jan 20247:00 amRNSDirector Dealing
8th Jan 20247:00 amRNSTrading Update and Change to Dividend Policy
11th Dec 20237:00 amRNSAcquisition of Insigniam LLC and Insigniam SAS
18th Sep 20237:00 amRNSInterim Results
18th Sep 20237:00 amRNSAcquisition of Responsum, Inc.
13th Jun 202310:45 amRNSResult of AGM
24th May 20231:31 pmRNSHolding(s) in Company
19th May 20237:00 amRNSPosting of Annual Report and Accounts
10th May 20233:00 pmRNSDirector/PCA Dealings
26th Apr 20237:00 amRNSGrant of Share Options
12th Apr 20237:00 amRNSAppointment of Joint Corporate Broker
4th Apr 20233:00 pmRNSDirector Dealing
3rd Apr 20239:15 amRNSDirector Dealing
3rd Apr 20237:00 amRNSFinal Results
28th Mar 20237:00 amRNSInvestor Presentation
27th Feb 20239:05 amRNSSecond Price Monitoring Extn
27th Feb 20239:00 amRNSPrice Monitoring Extension
27th Feb 20237:00 amRNSTrading Update
24th Feb 20232:05 pmRNSSecond Price Monitoring Extn
24th Feb 20232:00 pmRNSPrice Monitoring Extension
24th Feb 202311:05 amRNSSecond Price Monitoring Extn
24th Feb 202311:00 amRNSPrice Monitoring Extension
29th Nov 20221:15 pmRNSInvestor Presentation
11th Nov 20227:00 amRNSDirector Dealing
20th Oct 20227:00 amRNSPCA Dealing
6th Oct 20227:00 amRNSPurchase of Shares by Employee Benefit Trust
20th Sep 20227:00 amRNSInterim Results
12th Sep 20227:00 amRNSNotice of Interim Results
29th Jul 20224:41 pmRNSSecond Price Monitoring Extn
29th Jul 20224:35 pmRNSPrice Monitoring Extension
11th Jul 20221:45 pmRNSPDMR/PCA Dealing
7th Jul 202211:15 amRNSPCA Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.